Answers are grounded in this paper and cite their sources.
Cancer-associated fibroblast (CAF)-derived extracellular vesicles (EVs) have been implicated in colorectal cancer progression, but their associations with PROM1 and RAC1/PAK1 expression remain incompletely characterized. We examined the effects of CAF-derived EV preparations on metabolic activity and selected stemness- and epithelial–mesenchymal transition (EMT)-related transcripts in SW480 colorectal cancer cells. Preparations were obtained by ExoQuick precipitation, assessed by dynamic light scattering (DLS), and applied at 100 µg/mL for 48 h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays measured metabolic activity, and quantitative real-time PCR (qRT-PCR) measured relative PROM1, SNAI1, ZEB1, RAC1, and PAK1 mRNA levels. Separate experimental arms evaluated small interfering RNAs (siRNAs) targeting PROM1 or RAC1 (siPROM1 and siRAC1, respectively), each at 30 nM. Treatment with the preparations increased MTT activity and the expression of all five transcripts relative to untreated controls. siPROM1 and siRAC1 reduced their respective target mRNAs. In the PROM1 arm, ZEB1 and SNAI1 transcript levels and MTT activity were numerically lower in cells receiving EV preparations with siPROM1 than in cells receiving the preparations alone. In the RAC1 arm, PAK1 transcript levels and MTT activity were numerically lower with combined EV preparation and siRAC1 treatment than with preparations alone. These observations describe exploratory transcript-level and metabolic responses in a single colorectal cancer cell model and provide a basis for targeted functional validation.
No takes yet. Share an insight, caveat, or question.
Sabzi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: